Update on FOCUS Trial of CA4P in Ovarian Cancer Expected in Late Summer

Update on FOCUS Trial of CA4P in Ovarian Cancer Expected in Late Summer
Second preliminary results from the FOCUS Phase 2/3 trial assessing the safety and effectiveness of Mateon Therapeutics’ drug candidate CA4P in combination with standard-of-care therapies for platinum-resistant ovarian cancer are expected in coming months, the company announced. CA4P (combretastatin a4-phosphate), also known as fosbretabulin, was designed to target blood vessels and blood supply within tumors. This investigational drug is expected to deprive cancer cells from oxygen and nutrients, triggering their death. Mateon is currently sponsoring the Phase 2/3 FOCUS trial (NCT02641639) in platinum-resistant ovarian cancer patients. This multicenter, randomized study is expected to include about 430 patients who will receive CA4P or placebo in addition to the current standard-of-care therapy, which includes Avastin (bevacizumab) plus a chemotherapy chosen by the physician. Preliminary data released in April, obtained from the first 20 patients enrolled in the trial, showed positive results. Among the nine patients in the CA4P arm, two, or 22%, had partial responses, showing lesion size reduction of about 76% and 64%. Among the 11 placebo-treated patients, only one (9%) had a partial response, with a lesion reduction of 46%. In addition, the two patients receiving the investigational drug plus standard-of-care showed size reductions in lesions of about 76% and 64% compared to 46% tumor size reduction in the patient in the control arm. CA4P was shown to be well tolerate
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *